PSMB9 and nasopharyngeal carcinoma: Another therapeutic EBV vaccine, an adenovirus vector expressing LMP2, was tested in a phase I trial of patients with nasopharyngeal carcinoma in China (54); results of its effect on virus-specific T cells have not been reported.